NCT06489041 2026-02-02
Evaluating Microarray Pharmacogenetic Testing in Cancer Patients
Wake Forest University Health Sciences
Phase NA Recruiting
Clinical Trials
12 trialsNCT00981162 2022-09-13
Sorafenib Tosylate and Everolimus in Treating Patients With Advanced Solid Tumors and Metastatic Pancreatic Cancer That Does Not Respond to Gemcitabine Hydrochloride
Roswell Park Cancer Institute
Phase 1 Completed
NCT00936832 2022-08-30
Sunitinib Malate and Combination Chemotherapy as Front-Line Therapy in Treating Patients With Metastatic Rectal Cancer That Cannot Be Removed by Surgery
Federation Francophone de Cancerologie Digestive
Phase 2 Withdrawn
NCT01015833 2022-08-04
Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer
National Cancer Institute (NCI)
Phase 3 Completed
NCT01547923 2020-03-25
DPD côlon
Institut Cancerologie de l'Ouest
Phase NA Terminated
NCT00735917 2019-04-02
Saracatinib in Treating Patients With Previously Treated Metastatic Pancreatic Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00654160 2017-05-25
Irinotecan, Fluorouracil, and Leucovorin in Treating Patients With Advanced Gastrointestinal Cancer
Mayo Clinic
Phase 1 Completed
NCT01859182 2014-09-09
Selumetinib and Akt Inhibitor MK-2206 in Treating Patients With Refractory or Advanced Gallbladder or Bile Duct Cancer That Cannot Be Removed By Surgery
National Cancer Institute (NCI)
Phase 2 Withdrawn
NCT01205711 2014-07-08
FOLFERA
Cardiff University
Phase 2 Completed
NCT00088894 2013-06-05
Gemcitabine With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
National Cancer Institute (NCI)
Phase 3 Completed
NCT01324076 2011-05-13
Transarterial Chemoembolization Using Doxorubicin Beads With or Without Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery
National Cancer Institute (NCI)
Phase 3 Unknown
NCT00884767 2009-07-08
Biomarkers in Predicting Neurotoxicity in Patients With Colorectal Cancer Receiving Oxaliplatin
National Cancer Institute (NCI)
Phase 2 Unknown